Products for Research Use Only
RegisterLogin

Relamorelin (TFA)

CAT: 0804-HY-19884B-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-19884B-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Relamorelin (RM-131) TFA, a pentapeptide ghrelin analog, is a selective ghrelin/growth hormone secretagogue receptor (GHSR) agonist with a Ki of 0.42 nM for GHS-1a receptor. Relamorelin TFA is centrally penetrant. Relamorelin TFA increases growth hormone levels and accelerates gastric emptying. Relamorelin TFA has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research[1][2][3][4][5].
CAS Number
2863659-22-5
Product Name Alternative
RM-131 (TFA) ; BIM-28131 (TFA)
UNSPSC
12352209
Hazard Statement
H302, H315, H319, H335
Target
GHSR
Type
Peptides
Related Pathways
GPCR/G Protein
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/relamorelin-tfa.html
Purity
99.81
Solubility
H2O : 100 mg/mL (ultrasonic)
Smiles
NC(C1(NC([C@@H](NC([C@H](NC([C@H](NC(C2CCNCC2)=O)CC3=CSC4=CC=CC=C34)=O)CC5=CNC6=CC=CC=C56)=O)CC7=CC=CC=C7)=O)CCNCC1)=O.OC(C(F)(F)F)=O
Molecular Formula
C45H51F3N8O7S
Molecular Weight
905.00
Precautions
H302, H315, H319, H335
References & Citations
[1]DeBoer MD, et, al. Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology. 2007 Jun;148 (6) :3004-12.|[2]Fischer K, et, al. The Pentapeptide RM-131 Promotes Food Intake and Adiposity in Wildtype Mice but Not in Mice Lacking the Ghrelin Receptor. Front Nutr. 2015 Jan 12;1:31.|[3]Zatorski H, et, al. Relamorelin and other ghrelin receptor agonists - future options for gastroparesis, functional dyspepsia and proton pump inhibitors-resistant non-erosive reflux disease. J Physiol Pharmacol. 2017 Dec;68 (6) :797-805.|[4]Matthew Heckroth, et al. Nausea and Vomiting in 2021: A Comprehensive Update. J Clin Gastroenterol. 2021 Apr 1;55 (4) :279-299.|[5]Victor Chedid, et al. Relamorelin for the treatment of gastrointestinal motility disorders. Expert Opin Investig Drugs. 2017 Oct;26 (10) :1189-1197.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
Phase 3

Related Products

CatalogName
HY-19884Relamorelin
HY-19884ARelamorelin (acetate)
HY-P5380ATNO211 (TFA)
HY-P4668A-01Valylleucine (TFA)
HY-P11296A-01LLVK (TFA)
HY-P10927A-01BRP (TFA)
HY-P10333A-01LIH383 (TFA)
HY-P3970D-01KQFK (TFA)
HY-P3460A-01TDSRCVIGLYHPPLQVY (TFA)
HY-P1723ASpexin (TFA)

Alternative Products

CatalogName
MBS3847418-01Relamorelin TFA
PC111729Relamorelin (TFA)
A22838-50Relamorelin TFA 50mg
A22838-100Relamorelin TFA 100mg
A22838-25Relamorelin TFA 25mg
A22838-10Relamorelin TFA 10mg
A22838-5Relamorelin TFA 5mg
MBS5783789Relamorelin
MBS5799754Relamorelin acetate
A8967-1EZM0414 TFA

Popular Products